Why PainChek®?
FDA De Novo granted (DEN240073)
A unique, first-of-its-kind app-based medical device for US long-term care.
Clinically validated in the US
Validated through a pivotal clinical study in leading US skilled nursing facilities (SNFs).
Globally trusted
Proven over clinical use in Australia, New Zealand, the UK, and Canada since 2017.
12 million+ pain assessments completed worldwide.
Compliance
Supports compliance with CMS MDS 3.0 requirements, and federal and local pain management guidelines.
Staff empowerment
Equips healthcare teams with objective insights to guide informed, personalized care.
Seamless integration
Point-of-care, time-stamped assessments flow directly into eMAR and EHR platforms in real time.
“As an organization that is committed to, and focused on, the care of older adults, PainChek will play a meaningful role in enhancing the work that we do. It will have a positive impact on quality of life for our elders while helping our staff to better understand and effectively treat the residents.”
– Carol Silver-Elliott, President and CEO, Jewish Home Family

How PainChek® works
Available on smartphones and tablets, PainChek® uses evidence-based AI technology to automatically detect facial micro-expressions that indicate pain, along with digital checklists to record carer observations of other pain-related features.
All assessment data (but no facial images) is securely stored in PainChek®’s cloud portal, enabling continuous tracking of pain trends and treatment effectiveness.
PainChek® qualifies as an RTM-eligible medical deviceFor the first time, US healthcare providers can now claim reimbursement for pain monitoring through CMS, using PainChek®. This creates a new pathway to monitor and manage musculoskeletal pain in people with moderate to severe dementia who cannot reliably self-report their pain.
Transforming pain management globally
Across multiple studies and care settings in Australia, New Zealand, the UK, and Canada, PainChek® has consistently delivered measurable clinical outcomes:
Medication optimization: Reduced use of analgesics, antipsychotics, antidepressants, anxiolytics, and hypnotics
Resident well-being: Improved nutrition, increased mobility, reduced dependency, and improved quality of life
Safety and care quality: Fewer falls, reduced distress, and improved staff confidence in pain assessment
Operational benefits: Improved care efficiency and significant cost savings
Scottish Government-funded pilot: Key outcomes

REDUCTIONS:
25% reduction in analgesic use
40% reduction in falls
33% reduction in antipsychotic use
27% reduction in the use of anxiolytics and hypnotics
27% reduction in dependency scores
21% reduction in antidepressant use
INCREASE IN BMI SCORES
HIGH WORKFORCE APPROVAL
With a large majority of staff reporting PainChek® as an effective digital pain management solution
ESTIMATED ~£66 MILLION COST SAVINGS
For the Scottish aged care system over five years
Scottish Government-funded pilot: Key outcomes

25% reduction in analgesic use
40% reduction in falls
33% reduction in antipsychotic use
47% increase in BMI scores
27% reduction in the use of anxiolytics and hypnotics
27% reduction in dependency scores
21% reduction in antidepressant use

High workforce approval, with a large majority of staff reporting PainChek® as an effective digital pain management solution

Estimated ~£66 million cost savings for the Scottish aged care system over five years
Integration partners
PainChek’s rapidly expanding integration ecosystem includes 30+ leading technology partners worldwide, ensuring PainChek® works where your workflows live.
Free report: Prevention vs Reaction
Why leading care providers are rethinking their approach to pain management Body: See the clinical and financial case for shifting from reactive to proactive pain management in long-term care, and the measurable outcomes it delivers.


























